Objective. To evaluate the effects of mirogabalin on patient-reported pain and sleep interference in diabetic peripheral neuropathic pain (DPNP).
(R 2 5 0.4407), as were mean changes from baseline in ADSIS and ADPS at week 5 (R 2 5 0.6694). The mirogabalin 30 mg/day group showed significant improvement compared with placebo in four of six BPI subscales at end point; the mirogabalin 15 mg/day group showed significant improvement in three of six BPI subscales (P < 0.05). At end of treatment, the percentage of subject with PGIC status of "much improved or better" was greater in all mirogabalin dose groups than in the placebo group (P < 0.05). A low incidence of treatment-related adverse events was reported for mirogabalin. Mirogabalin is a novel, preferentially selective a2d-1 ligand intended for treatment of pain associated with fibromyalgia and neuropathic pain. In a randomized, double-blind, placebo-controlled and active comparator (pregabalin)-controlled, adaptive proof-of-concept phase II study in patients with diabetic peripheral neuropathic pain (DPNP), mirogabalin significantly improved pain-associated sleep interference at the 15, 20, and 30 mg/day dose levels compared with placebo. Baseline average daily sleep interference score (ADSIS) and average daily pain score (ADPS) values at baseline were strongly correlated (R
Introduction
Diabetic peripheral neuropathic pain (DPNP) is reported in up to 50% of patients with chronic diabetes and is associated with significant morbidity and reduced quality of life [1] [2] [3] [4] . DPNP is frequently unreported and, consequently, often goes untreated [3] . Symptoms of burning or lancinating pain, electric shock-type pain shooting down the legs, uncomfortable tingling (paresthesia), and contact pain (allodynia) are experienced by approximately one-third of patients with DPNP [1, 2] . These symptoms are generally worse at night and can result in sleep disturbances, anxiety, and depression [1, 4] .
There is increasing evidence that the relationship between pain and sleep is bidirectional, such that pain increases sleep disturbance and disturbed sleep intensifies pain [5, 6] . Although the exact mechanisms underlying this relationship are unclear, neuroendocrine and autonomic mechanisms seem to contribute to, and may be influenced by, pain and sleep [7, 8] .
Mechanistically, sleep deprivation seems to impair descending pain inhibition pathways that are important in controlling and coping with pain [7] . In support of this premise, there is evidence that good quality sleep helps to resolve pain. In the EPIFUND study, 1,061 subjects with chronic pain were evaluated using the Estimation of Sleep Problems Scale, which measures sleep onset, maintenance, early wakening, and restorative sleep. Univariate analysis of total sleep scores showed that subjects who had the best quality sleep were 60% more likely to report resolution of chronic pain than those with poor-quality sleep [9] . Adjusted univariate analysis confirmed that restorative sleep, but not rapid sleep onset or absence of early wakening, was associated with the resolution of chronic pain [9] .
Sleep disturbances as a result of nocturnal pain are commonly reported in patients with DPNP [10] . Between 72% and 96% of patients with DPNP have moderately to severely affected sleep, particularly with regard to sleep adequacy, sleep interruption, and awakening with shortness of breath or headache [10] . Sleep disturbances are common in patients with persistent pain and are a well-established risk factor for depression, independent of the pain itself [10, 11] . Evidence increasingly indicates that, in addition to clinician focus on pain management, it might be important to address sleep impairment in patients with DPNP [10, 11] .
Initial management of DPNP is focused on achieving and maintaining tight glycemic control [1] ; precautions are taken to avoid lowering A1c too rapidly, which might result in treatment-induced neuropathy [12] . Because glycemic control is not easily attained and does not relieve pain in diabetic patients, a number of nonantidiabetic agents are used to provide symptomatic relief of DPNP. However, only two medications-the serotonin-norepinephrine reuptake inhibitor duloxetine and the anticonvulsant pregabalin-are approved by the US Food and Drug Administration (FDA) [2, 13, 14] . Tapentadol is approved by the FDA for neuropathic pain associated with diabetic peripheral neuropathy, but only in patients with severe pain that requires around-theclock, long-term treatment and for whom alternative treatment options are inadequate [15] . Both agents, in addition to tricyclic antidepressants and the anticonvulsant gabapentin, are recommended as first-and second-line treatments for DPNP, depending upon contraindications and comorbidities [2] . Nevertheless, a lack of effectiveness or loss of responsiveness over time, as well as the occurrence of intolerable adverse effects, often prompts patients with DPNP to seek other treatment options, which highlights the unmet need for effective, well-tolerated therapies [2] .
Comparative data indicate that agents commonly used in the management of DPNP have variable effects on sleep parameters [16] [17] [18] . Results from a randomized controlled trial that compared the effect of pregabalin 600 mg/day, amitriptyline 75 mg/day, and duloxetine 120 mg/day on polysomnographic sleep in patients with chronic DPNP showed that pregabalin improved sleep continuity, duloxetine increased wake time and reduced total sleep time, and amitriptyline had no effect on sleep efficiency or total sleep time but reduced wake after sleep onset time compared with placebo at baseline [17] . According to a pooled analysis of 16 placebocontrolled pregabalin trials of patients with DPNP or postherpetic neuralgia [18] , the greatest pain relief was observed in patients with severe sleep interference at baseline. Moreover, sleep interference scores at baseline were a moderately good predictor of global pain improvement after fixed-or flexible-dose pregabalin (75-600 mg/ day for up to 13 weeks). Given the well-established association between poor sleep and pain severity [10] , analgesic agents that also improve sleep might warrant greater consideration when initiating treatment for DPNP.
Mirogabalin (Daiichi Sankyo Co., Ltd., Tokyo, Japan) is a novel, preferentially selective a2d-1 ligand [19] intended for treatment of pain associated with fibromyalgia and neuropathic pain. The safety and efficacy of mirogabalin were evaluated in a randomized, double-blind, placeboand active comparator (pregabalin)-controlled, adaptive proof-of-concept phase II study in patients with DPNP [20] . Mirogabalin administered once or twice daily (5-30 mg/day) produced early and sustained reductions in ADPS relative to placebo (P < 0.05 for mirogabalin 15, 20, and 30 mg/day dose levels). After five weeks of treatment, up to 67% of patients achieved at least a 30% reduction in ADPS and up to 44% achieved at least a 50% reduction [20] . By comparison, 38% of patients receiving pregabalin 300 mg/day in this study achieved a pain reduction of at least 30%, relative to baseline, and there were no significant differences compared with placebo after five weeks of treatment. Mirogabalin was well tolerated and demonstrated a balanced safety profile across the dose range, with a low overall rate of adverse events (AEs) [20] .
Herein, we present additional secondary end points from this trial, which measured the effects of mirogabalin on patient-reported pain and sleep interference using patient global impression of change (PGIC), brief pain inventory (BPI), and ADSIS assessments.
Methods
This study (Clinicaltrials.gov identifier NCT01496365) was conducted between November 28, 2011, and September 7, 2012, at 80 US sites. Details of the study design have been published elsewhere [20] . Briefly, adults age 18 years or older with type 1 or 2 diabetes and glycosylated hemoglobin (HbA1c) of 10% or less at screening and on a stable antidiabetic medication regimen for 30 or more days were in enrolled in this study if they had painful distal symmetric sensorimotor polyneuropathy for six or more months based on medical history or examination; pain score of 40 mm or greater on the short-form McGill Pain Questionnaire (SF-MPQ) visual analog scale (VAS) at screening and randomization, and ADPS of 4 or higher based on the 11-point numeric rating scale (pain NRS; calculated from a minimum of four pain ratings in daily diary entries obtained during the baseline period) at randomization. Subjects were excluded if they had a diagnosis of mononeuropathy, major psychiatric disorders, and known sensitivity to pregabalin and gabapentin. Patients in whom prior therapy with pregabalin or gabapentin was unsuccessful (i.e., lack of efficacy after full titration to effective doses [up to 300 mg/day for pregabalin]) were excluded. Table 1 ). Upon awakening and prior to taking study medications, patients were instructed to rate pain and sleep interference in diaries using an NRS. ADSIS has 11 possible responses, ranging from 0 ¼ "pain does not interfere with sleep" to 10 ¼ "pain completely interferes with sleep." The modified BPI is now considered the gold standard in the assessment of pain across many conditions. It contains 15 items in six subscales and assesses for the presence of pain, pain intensity, and functional interference from pain over the previous 24 hours [21] . It is rated on an 11-point NRS from 0 ¼ "no pain" to 10 ¼ "pain as bad as you can imagine." The PGIC assesses how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention [22] . PGIC had seven possible responses for overall status since start of the study: very much improved, much improved, minimally improved, no change, minimally worse, much worse, and very much worse.
Safety assessments were performed at each clinic visit and one week after the end of treatment. Safety was assessed based on treatment-emergent AEs (TEAEs), including AEs of specific interest. All participating clinical sites received institutional review board approval of the study protocol and study-related documents prior to enrollment, and all subjects provided written informed consent.
Statistical Analyses
SAS (version 9.2 or higher; SAS Institute, Cary, NC, USA) was used to produce all summary tables, figures, and data listings. Unless otherwise specified, last observation carried forward (LOCF) was used to address missing data, and analyses were two-sided and performed at the 0.05 level. The full analysis set comprised all randomly assigned subjects who received one or more doses of study medication and had one or more postrandomization pain ratings in addition to a baseline value (N ¼ 433). The safety analysis set included all subjects who received one or more doses of study medication (N ¼ 435).
The observed ADSIS was summarized by treatment and measurement time (baseline, weeks 1-5, and end point [week 5/LOCF]) as the average of the last seven available daily scores. Analysis of covariance (ANCOVA) was conducted on the full analysis set, with the treatment arm as the factor and baseline ADSIS as the covariate. An overall contrast test (all mirogabalin dose arms vs placebo) was also conducted. Corresponding P values and 95% confidence intervals (CIs) were provided for each contrast. For the modified BPI assessment, ANCOVA was conducted on the full analysis set, using week 5/LOCF and comparing active treatment with placebo and mirogabalin doses with pregabalin.
The PGIC was recorded at the end of treatment/early termination visit and analyzed based on the following definitions: 1) subject overall status was minimally improved or better (i.e., score 3) and 2) patient overall status was much improved or better (i.e., score 2). Comparisons between treatment arms were conducted separately using a chi-square test, CIs were constructed, and two-sided P values were calculated.
Results

Subject Demographics and Baseline Characteristics
A total of 913 subjects were screened; of these, 452 were randomly assigned to receive treatment (242 men and 210 women) and 85% (383/452) completed the study. Subject demographics and baseline characteristics are reported elsewhere [20] . Briefly, subjects were predominantly white (75%) with a mean age of 60.1 (69.3) years. Most (91.8%) subjects had type 2 diabetes and had a mean duration of DPNP of 5.8 years. Subject demographics were similar across the treatment groups [20] .
Efficacy
A significant improvement in ADSIS relative to placebo was observed starting at week 1 for the mirogabalin 15 and 30 mg/day groups and at week 2 for the mirogabalin 20 mg/day group and continuing through week 5 (P < 0.05) ( Figure 1A) . At week 5, statistically significant reductions in ADSIS were observed in the mirogabalin 15, 20, and 30 mg/day groups compared with placebo ( Figure 1B) . The reduction in ADSIS observed with mirogabalin 15 mg/day was significantly different from pregabalin from week 4 until the end of treatment (P < 0.05) ( Figure 1B) . No significant differences in ADSIS were observed for pregabalin compared with placebo.
Correlation plots were generated to evaluate the relationship between ADSIS and ADPS. Baseline ADSIS and ADPS values at baseline were strongly correlated (R 2 ¼ 0.4407) (Figure 2A ), as were mean change from baseline in ADSIS and ADPS values at week 5 (R 2 ¼ 0.6694) ( Figure 2B ).
The mirogabalin 30 mg/day group showed significant improvements in change from baseline to end point compared with placebo in four of six BPI subscales, and the mirogabalin 15 mg/day group showed significant improvements in change from baseline to end point in three of six BPI subscales (P < 0.05) ( Table 1) . Changes from baseline in pain right now or relief from pain were not significantly different from that with placebo for any mirogabalin dose group. Pregabalin was not significantly different from placebo for any subscale.
At end of treatment (week 5 or early discontinuation), the percentage of subjects with overall status of "much improved or better" for the PGIC was greater in the mirogabalin 5 mg/day (49.1%), 10 mg/day (54.5%), 15 mg/ day (48.0%), 20 mg/day (48.1%), and 30 mg/day (50.0%) groups than in the placebo group (31.1%) (P < 0.05) ( Figure 1C ). At the end of treatment (week 5) or early termination, the percentage of patients with overall status of "minimally improved or better" for the PGIC was also greater in all mirogabalin dose groups than in the placebo group. These differences were statistically significant for mirogabalin 5, 10, and 30 mg/day. No significant differences were observed for pregabalin compared with placebo in either PGIC assessment.
Safety and Tolerability
Mirogabalin was well tolerated across the dose range; dizziness (9.4%), somnolence (6.1%), and headache (6.1%) were the most commonly reported TEAEs. The overall safety and tolerability profile of mirogabalin has been reported elsewhere [20] . Overall, 20.9% of patients experienced TEAEs of special interest in the combined mirogabalin dose groups, compared with 28.0% in the pregabalin group and 7.4% in the placebo group (Table 2) . Central nervous system-related events were the most common TEAEs of special interest, and most TEAEs in this category were mild and resolved by study end. There were no clinically meaningful changes in edema and edema-related events or weight gain in the mirogabalin groups, and less than 5% of subjects reported visual disturbances (Table 2) . TEAEs related to abuse potential were assessed; one subject who received mirogabalin 30 mg/day reported having euphoric mood, for which severity was moderate and resolved by the end of the study. Neither pregabalin nor mirogabalin had any effect with regard to anxiety or depression, as measured by the Hospital Anxiety and Depression Scale (HADS) subscales. However, mean HADS scores at baseline ranged from 7.1 to 8.0 for the anxiety subscale (0-7 is considered normal), which is borderline and, therefore, may have precluded the detection of treatment effects on anxiety and depression at the five-week end point. 
Conclusions
In this five-week study, mirogabalin demonstrated improvement in patient-reported pain and sleep assessments compared with placebo. Mirogabalin significantly improved pain-associated sleep interference at the 15, 20, and 30 mg/day dose levels compared with placebo. In addition, the proportion of subjects who Figure 2 Correlation plots of (A) weekly ADPS and ADSIS at baseline and (B) weekly ADPS change from baseline and ADSIS change from baseline at week 5 (LOCF).
reported at the end of the study that they felt "much improved" or "very much improved" was significantly higher at each mirogabalin dose level relative to placebo. Other secondary efficacy end points, such as the modified BPI, favored mirogabalin over placebo, although the differences were not significant for each dose group. Pregabalin 300 mg/day was generally not significantly different than placebo across the secondary end points assessed in this study.
ADSIS and ADPS scores were strongly correlated at baseline and at week 5 for the combined analysis of all subjects. The small sample size in each treatment group precluded correlative analyses based on treatment assignment. Nevertheless, this pooled correlation provides evidence of the robustness of the current study, although further investigation is necessary to delineate the relationship between reductions in pain and improvements in sleep. Subjectively improved sleep might be a clinically relevant secondary effect of reduced pain and might have an impact on treatment decisions in regard to the optimal pain management strategy [17] . Phase III studies of mirogabalin efficacy and safety in patients with DPNP will provide an opportunity to explore these relationships further and to potentially evaluate the predictive value of sleep interference on response to treatment.
The improvement in sleep parameters observed with mirogabalin is similar to that reported in recent studies of pregabalin in patients with neuropathic pain [18, 23, 24] . In patients with DPNP or postherpetic neuralgia (PHN), rapid (within one day for some patients) and sustained improvement in daily sleep interference scores was reported with pregabalin fixed-or flexible-dose regimens (75-600 mg/day) in a post hoc analysis of more than 4,500 patients enrolled in 16 placebo-controlled studies of five to 13 weeks' duration [24] . The authors of that post hoc analysis recommend caution in the interpretation of the results because of the variations in the design of the included studies and because the studies were not designed to evaluate time to improvement in pain-related sleep interference [24] . However, these findings are supported by an observational study that reported significant improvement in the primary end point of pain-related sleep interference with pregabalin (25-300 mg/day) relative to usual care with conventional analgesia in patients with chronic low back pain with accompanying neuropathic pain [23] . Baseline pain sleep interference scores also seem to be a relatively good predictor of global patient improvement, with a high degree of association between improvement in sleep and pain relief in patients with DPNP [18] . In a post hoc analysis of more than 4,500 patients (including more than 3,000 patients with DPNP), the extent of improvement in pain scores was proportionate to the severity of the baseline sleep disturbance: the greatest pain relief was recorded in patients with severe sleep disturbance [18] .
Mirogabalin displayed a balanced safety profile across all study treatments, and a low overall rate of AEs [20] and AEs of special interest was observed. Most TEAEs were mild to moderate and resolved at the end of the study duration.
The results of the current study are strengthened by the robust study design. However, this study has a number of limitations that have been discussed previously [20] . Although the effects of pregabalin 300 mg/day were similar to those of placebo, 300 mg/day might be an ineffective dose and might have been too low to produce any clinically meaningful impact on pain and sleep parameters. Pregabalin is indicated for the treatment of DPNP by the FDA at doses of up to 300 mg/ day [25] . In clinical trials, pregabalin is generally administered at doses ranging from 300 to 600 mg/day, and significant reduction in pain has been observed at 600 mg/day [26, 27] . However, at this dose, pregabalin is also associated with an increased incidence of somnolence and dizziness, approaching 25% and 50%, respectively, and withdrawal rates of 25% have been reported in patients receiving a fixed-dose regimen of 600 mg in two divided doses [27] .
Recent evidence suggests that the presence of comorbid sleep disturbances in patients with DPNP might play a role in predicting pain relief in response to pregabalin [18] . Based on the current data, it is not possible to predict responsiveness to mirogabalin. Therefore, a larger, equally well-designed study is necessary to confirm the current results and lend robust support to these initial findings.
Following from the favorable outcomes observed with mirogabalin in this phase II study, ongoing phase III studies aim to elucidate the efficacy, safety, and patient benefit of mirogabalin in patients with DPNP (NCT02318706), fibromyalgia (NCT02146430 and NCT02496884), and PHN (NCT02318719). 
